Pulmonx Corp. (LUNG) News
Filter LUNG News Items
LUNG News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
LUNG News Highlights
- For LUNG, its 30 day story count is now at 2.
- Over the past 12 days, the trend for LUNG's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about LUNG are DEC, HNST and SE.
Latest LUNG News From Around the Web
Below are the latest news stories about PULMONX CORP that investors may wish to consider to help them evaluate LUNG as an investment opportunity.
Insider Sell: President and CEO French Glendon E. III Sells 10,000 Shares of Pulmonx Corp (LUNG)Pulmonx Corp (NASDAQ:LUNG), a company specializing in medical devices for the treatment of pulmonary disorders, has reported an insider sell according to a recent SEC filing. |
The Honest Company Announces Appointment of Michael Barkley, Alissa Hsu Lynch, and Andrea Turner to the Board of DirectorsLOS ANGELES, Dec. 11, 2023 (GLOBE NEWSWIRE) -- The Honest Company (NASDAQ: HNST), a digitally-native consumer products company dedicated to creating clean- and sustainably-designed products spanning baby care, beauty, personal care, wellness and household care, today announced that Michael Barkley, Former Chief Executive Officer of Kind LLC, Alissa Hsu Lynch, Former Global Head of MedTech Strategy and Solutions for Google Cloud, and Andrea Turner, Former Senior Vice President, Global Customer Se |
Biotech Breakthroughs: 3 Revolutionary Stocks Redefining HealthcareThe article embarks on a transformative journey through the biopharmaceutical frontier, where the listed companies stand as titans reshaping healthcare norms. |
Pulmonx to Present at the Piper Sandler 35th Annual Healthcare ConferenceREDWOOD CITY, Calif., Nov. 15, 2023 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the company will be participating in a fireside chat at the Piper Sandler 35th Annual Healthcare Conference in New York on Wednesday, November 29, 2023, at 11:00 AM PT / 2:00 PM ET. A live and archived webcast of the presentation will be available on “Investors” section of the Pulmonx website at https://in |
Pulmonx to Participate at Upcoming Investor ConferencesREDWOOD CITY, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the company will be participating in two upcoming investor conferences. Pulmonx management is scheduled to participate in a fireside chat at the Stifel 2023 Healthcare Conference in New York on Tuesday, November 14, 2023, at 11:25am PT / 2:25pm ET. Interested parties may access a live and archived webcast |
Pulmonx Corporation (NASDAQ:LUNG) Q3 2023 Earnings Call TranscriptPulmonx Corporation (NASDAQ:LUNG) Q3 2023 Earnings Call Transcript October 30, 2023 Pulmonx Corporation beats earnings expectations. Reported EPS is $-0.39, expectations were $-0.45. Operator: Thank you for standing by. Welcome to the Pulmonx Third Quarter 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speaker’s presentation, there will […] |
Q3 2023 Pulmonx Corp Earnings CallQ3 2023 Pulmonx Corp Earnings Call |
Pulmonx Corporation (LUNG) Reports Q3 Loss, Tops Revenue EstimatesPulmonx Corporation (LUNG) delivered earnings and revenue surprises of 13.33% and 10.67%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock? |
Pulmonx Corp (LUNG) Reports Record Q3 2023 Financial ResultsRevenue and U.S. sales hit record highs, with a 31% and 41% increase respectively |
Pulmonx Reports Record Third Quarter 2023 Financial ResultsREDWOOD CITY, Calif., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported financial results for the third quarter of 2023 ended September 30, 2023. Recent Highlights Achieved record worldwide revenue of $17.7 million in the third quarter of 2023, a 31% increase over the same period last year and an increase of 29% on a constant currency basisDelivered a record $11.8 mi |